The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis

Current Vascular Pharmacology

Volumn 8, Issue 6, 2010, Pages 792-803

  Karagiannis, Asterios ^a   Tziomalos, Konstantinos ^b   Anagnostis, Panagiotis ^a   Gossios, Thomas D ^a   Florentin, Matilda ^c   Athyros, Vasilios G ^a   Mikhailidis, Dimitri P ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Calcium channel block ers; Diabetes mellitus; Diuretics; Fibrinolysis; Insulin sensitivity; Lipids; Thrombosis; blockers

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANTIGEN; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; CHOLESTEROL; DILTIAZEM; ENALAPRIL; FELODIPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; ISRADIPINE; LIPID; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; NIFEDIPINE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; ROSIGLITAZONE; TISSUE PLASMINOGEN ACTIVATOR; TRANDOLAPRIL; TRIACYLGLYCEROL; UNINDEXED DRUG;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFECT; GLUCOSE METABOLISM; HEMOSTASIS; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78649365900     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110793563906     Document Type: Article

References (181)

1. Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trialsof drug treatment for hypertension. Hypertension 1989; 13 (Suppl5): I36-I44.
2. Chalmers J, Zanchetti A. The 1996 report of a World Health Organizationexpert committee on hypertension control. J Hypertens 1996; 14: 929-33.
3. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associatedwith antihypertensive therapies used as first-line agents. A systematicreview and meta-analysis. JAMA 1997; 277: 739-45.
4. World Health Organization-International Society of HypertensionBlood Pressure Lowering Treatment Trialists' Collaboration. Protocolfor prospective collaborative overviews of major randomizedtrials of blood-pressure-lowering treatments. J Hypertens 1998; 16:127-37.
5. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines forthe Management of Arterial Hypertension: The Task Force for theManagement of Arterial Hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology(ESC). J Hypertens 2007; 25: 1105-87.
6. Sarafidis PA, Bakris GL. Antihypertensive therapy and the risk ofnew-onset diabetes. Diabetes Care 2006; 29: 1167-9.
7. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensivetherapy on serum lipids. Ann Intern Med 1995; 122: 133-41.
8. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertensionand antihypertensive therapy as risk factors for type 2 diabetesmellitus. Atherosclerosis Risk in Communities Study. N EnglJ Med 2000; 342: 905-12.
9. Suter PM, Vetter W. Metabolic effects of antihypertensive drugs. JHypertens 1995; 13(4 Suppl): S11-S17.
10. Karagiannis A, Mikhailidis DP, Kakafika AI, Tziomalos K, Athyros VG. Atenolol: differences in mode of action comparedwith other antihypertensives. An opportunity to identify featuresthat influence outcome? Curr Pharm Des 2007; 13: 229-39.
11. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred fordyslipidemia. Am J Hypertens 1999; 12: 673-81.
12. Papadakis JA, Mikhailidis DP, Vrentzos GE, Kalikaki A, Kazakou I, Ganotakis ES. Effect of antihypertensive treatment on plasma fibrinogenand serum HDL levels in patients with essential hypertension.Clin Appl Thromb Hemost 2005; 11: 139-46.
13. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. Theeffects of antihypertensive therapy on haemostatic parameters. CurrPharm Des 2003; 9: 2445-64.
14. Kakafika AI, Liberopoulos EN, Karagiannis A, Athyros VG, Mikhailidis DP. Dyslipidaemia, hypercoagulability and the metabolicsyndrome. Curr Vasc Pharmacol 2006; 4: 175-83.
15. Sowers JR. Insulin resistance and hypertension. Am J PhysiolHeart Circ Physiol 2004; 286: H1597-H1602.
16. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR. Serum-insulin in essential hypertension and in peripheral vasculardisease. Lancet 1966; 1: 1336-7.
17. Berglund G, Larsson B, Andersson O, et al. Body composition andglucose metabolism in hypertensive middle-aged males. Acta MedScand 1976; 200: 163-9.
18. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance inessential hypertension. N Engl J Med 1987; 317: 350-7.
19. Lissner L, Bengtsson C, Lapidus L, Kristjansson K, Wedel H. Fasting insulin in relation to subsequent blood pressure changesand hypertension in women. Hypertension 1992; 20: 797-801.
20. Haffner SM, Ferrannini E, Hazuda HP, Stern MP. Clustering ofcardiovascular risk factors in confirmed prehypertensive individuals.Hypertension 1992; 20: 38-45.
21. Ferrari P, Weidmann P, Shaw S, et al. Altered insulin sensitivity,hyperinsulinemia, and dyslipidemia in individuals with a hypertensiveparent. Am J Med 1991; 91: 589-96.
22. Allemann Y, Horber FF, Colombo M, et al. Insulin sensitivity andbody fat distribution in normotensive offspring of hypertensiveparents. Lancet 1993; 341: 327-31.
23. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impairedglucose tolerance and hypertension. Am Heart J 1991; 121 (4 Pt 2):1268-73.
24. Fletcher A, Amery A, Birkenhäger W, et al. Risks and benefits inthe trial of the European Working Party on High Blood Pressure inthe Elderly. J Hypertens 1991; 9: 225-30.
25. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, lowdose,diuretic-based, antihypertensive therapy on glucose, lipid,uric acid, and potassium levels in older men and women with isolatedsystolic hypertension: The Systolic Hypertension in the ElderlyProgram. SHEP Cooperative Research Group. Arch InternMed 1998; 158: 741-51.
26. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fataloutcomes in subjects with isolated systolic hypertension with andwithout diabetes. Am J Cardiol 2005; 95: 29-35.
27. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the developmentof diabetes. JAMA 2001; 286: 1882-5.
28. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patientswith chronic heart failure: insight from the Studies Of Left VentricularDysfunction (SOLVD). Circulation 2003; 107: 1291-6.
29. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition andPrognosis in the Elderly (SCOPE): principal results of a randomizeddouble-blind intervention trial. J Hypertens 2003; 21: 875-86.
30. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The FelodipineEvent Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157-72.
31. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartanon mortality and morbidity in patients with chronic heart failure:the CHARM-Overall programme. Lancet 2003; 362: 759-66.
32. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensinconverting-enzyme inhibition in stable coronary artery disease. NEngl J Med 2004; 351: 2058-68.
33. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on theincidence of diabetes. N Engl J Med 2006; 355: 1551-62.
34. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers vs.diuretics in hypertensive men: main results from the HAPPHYtrial. J Hypertens 1987; 5: 561-72.
35. ALLHAT Officers and Coordinators for the ALLHAT CollaborativeResearch Group. Major outcomes in high-risk hypertensive patientsrandomized to angiotensin-converting enzyme inhibitor orcalcium channel blocker vs. diuretic: The Antihypertensive andLipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA 2002; 288: 2981-97.
36. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipineGITS or Co-amilozide in hypertensive diabetics and non-diabeticsin Intervention as a Goal in Hypertension (INSIGHT).Hypertension 2003; 41: 431-6.
37. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapyon VASCULAR morbidity and mortality in hypertension: the CaptoprilPrevention Project (CAPPP) randomised trial. Lancet 1999;353: 611-6.
38. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial ofeffects of calcium antagonists compared with diuretics and betablockerson VASCULAR morbidity and mortality in hypertension:the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.
39. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of oldand new antihypertensive drugs in elderly patients: CV mortalityand morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
40. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detectedhypertensives: results of the Antihypertensive Treatment and LipidProfile in a North of Sweden Efficacy Evaluation (ALPINE study).J Hypertens 2003; 21: 1563-74.
41. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of CV eventswith an antihypertensive regimen of amlodipine adding perindoprilas required vs. atenolol adding bendroflumethiazide as required, inthe Anglo-Scandinavian Cardiac Outcomes Trial-Blood PressureLowering Arm (ASCOT-BPLA): a multicentre randomised controlledtrial. Lancet 2005; 366: 895-906.
42. Dahlöf B, Devereux RB, Kjeldsen SE, et al. CV morbidity andmortality in the Losartan Intervention For Endpoint reduction inhypertension study (LIFE): a randomised trial against atenolol.Lancet 2002; 359: 995-1003.
43. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calciumantagonist vs. a non-calcium antagonist hypertension treatmentstrategy for patients with coronary artery disease. The InternationalVerapamil-Trandolapril Study (INVEST): a randomized controlledtrial. JAMA 2003; 290: 2805-16.
44. Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan comparedto amlodipine on preventing type 2 diabetes in high-risk hypertensivepatients: the VALUE trial. J Hypertens 2006; 24: 1405-12.
45. Thornley-Brown D, Wang X, Wright JT Jr, et al. Differing effectsof antihypertensive drugs on the incidence of diabetes mellitusamong patients with hypertensive kidney disease. Arch Intern Med 2006; 166: 797-805.
46. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications andthe risk of incident type 2 diabetes. Diabetes Care 2006; 29: 1065-70.
47. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensivedrugs: a network meta-analysis. Lancet 2007; 369:201-7.
48. Lithell HO. Effect of antihypertensive drugs on insulin, glucose,and lipid metabolism. Diabetes Care 1991; 14: 203-9.
49. Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate,lipid, and potassium metabolism. Am Heart J 1983; 106(1 Pt 2): 245-51.
50. Gorden P, Sherman BM, Simopoulos AP. Glucose intolerance withhypokalemia: an increased proportion of circulating proinsulin-likecomponent. J Clin Endocrinol Metab 1972; 34: 235-40.
51. Helderman JH, Elahi D, Andersen DK, et al. Prevention of theglucose intolerance of thiazide diuretics by maintenance of bodypotassium. Diabetes 1983; 32: 106-11.
52. Lund-Johansen P. The role of drugs in countering adverse pathophysiologicalprofiles: influence on hemodynamics. Am Heart J 1987; 114 (4 Pt 2): 958-64.
53. Lund-Johansen P, Omvik P, Nordrehaug JE. Long-term hemodynamiceffects of antihypertensive treatment. Clin Investig 1992; 70(Suppl 1): S58-S64.
54. Lithell H, Pollare T, Berne C, Saltin B. The metabolic and circulatoryresponse to beta-blockade in hypertensive men is correlated tomuscle capillary density. Blood Press 1992; 1: 20-6.
55. Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, LjunghallS. Metabolic effects of diltiazem and atenolol: results from a randomized,double-blind study with parallel groups. J Hypertens 1989; 7: 551-9.
56. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol andpropranolol in a double-blind cross-over study in hypertensive patients.Blood Press 1992; 1: 92-101.
57. Rössner S, Taylor CL, Byington RP, Furberg CD. Long term propranololtreatment and changes in body weight after myocardial infarction.BMJ 1990; 300: 902-3.
58. Caro JF. Insulin resistance in obese and non-obese man. J ClinEndocrinol Metab 1991; 73: 691-5.
59. UK Prospective Diabetes Study Group. Efficacy of atenolol andcaptopril in reducing risk of macrovascular and microvascularcomplications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
60. Malminiemi K. Association between serum lipids, glucose tolerance,and insulin sensitivity during 12 months of celiprolol treatment.Cardiovasc Drugs Ther 1995; 9: 295-304.
61. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects ofcarvedilol vs. metoprolol in patients with type 2 diabetes mellitusand hypertension: a randomized controlled trial. JAMA 2004; 292:2227-36.
62. Koyama Y, Kodama K, Suzuki M, Harano Y. Improvement ofinsulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens 2002; 15: 927-31.
63. Yagi S, Goto S, Yamamoto T, Kurihara S, Katayama S. Effect ofcilnidipine on insulin sensitivity in patients with essential hypertension.Hypertens Res 2003; 26: 383-7.
64. Begum N, Sussman KE, Draznin B. Calcium-induced inhibition ofphosphoserine phosphatase in insulin target cells is mediated by thephosphorylation and activation of inhibitor 1. J Biol Chem 1992;267: 5959-63.
65. McKeage K, Scott LJ. Manidipine: a review of its use in the managementof hypertension. Drugs 2004; 64: 1923-40.
66. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, CooperME. Why blockade of the renin-angiotensin system reduces the incidenceof new-onset diabetes. J Hypertens 2005; 23: 463-73.
67. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effectsof antihypertensive drugs. Am Heart J 1994; 128 (6 Pt 1): 1177-83.
68. Agarwal R, Campbell RC, Warnock DG. Oxidative stress in hypertensionand chronic kidney disease: role of angiotensin II. SeminNephrol 2004; 24: 101-14.
69. Allon M, Takeshian A, Shanklin N. Effect of insulin-plus-glucoseinfusion with or without epinephrine on fasting hyperkalemia. KidneyInt 1993; 43: 212-7.
70. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensinconvertingenzyme inhibitors and angiotensin II receptor antagonists:beyond the renin-angiotensin system. J Hypertens 2004; 22:2253-61.
71. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensintype 1 receptor blockers induce peroxisome proliferator-activatedreceptor-gamma activity. Circulation 2004; 109: 2054-7.
72. Uwaifo GI, Ratner RE. Novel pharmacologic agents for type 2diabetes. Endocrinol Metab Clin North Am 2005; 34: 155-97.
73. Karagiannis A, Mikhailidis DP, Athyros VG, et al. The role ofrenin-angiotensin system inhibition in the treatment of hypertensionin metabolic syndrome: are all the angiotensin receptor blockersequal? Expert Opin Ther Targets 2007; 11: 191-205.
74. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropicrole of white adipose tissue. Br J Nutr 2004; 92: 347-55.
75. Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mikhailidis DP. Should adipokines be considered in the choice ofthe treatment of obesity-related health problems? Curr Drug Targets 2010; 11: 122-35.
76. Leclercq-Meyer V, Herchuelz A, Valverde I, Couturier E, Marchand J, Malaisse WJ. Mode of action of clonidine upon isletfunction: dissociated effects upon the time course and magnitude ofinsulin release. Diabetes 1980; 29: 193-200.
77. Haenni A, Lithell H. Moxonidine improves insulin sensitivity ininsulin-resistant hypertensives. J Hypertens Suppl 1999; 17: S29-S35.
78. Jacob S, Klimm HJ, Rett K, Helsberg K, Häring HU, Gödicke J. Effects of moxonidine vs. metoprolol on blood pressure and metaboliccontrol in hypertensive subjects with type 2 diabetes. ExpClin Endocrinol Diabetes 2004; 112: 315-22.
79. Khoury AF, Kaplan NM. Alpha-blocker therapy of hypertension.An unfulfilled promise. JAMA 1991; 266: 394-8.
80. Andersson PE, Lithell H. Metabolic effects of doxazosin andenalapril in hypertriglyceridemic, hypertensive men. Relationshipto changes in skeletal muscle blood flow. Am J Hypertens 1996; 9(4 Pt 1): 323-33.
81. The Hypertension Detection and Follow-up Program CooperativeResearch Group. Mortality findings for stepped-care and referredcareparticipants in the hypertension detection and follow-up program,stratified by other risk factors. Prev Med 1985; 14: 312-35.
82. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significanceof new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-9.
83. Alderman MH, Cohen H, Madhavan S. Diabetes and CV events inhypertensive patients. Hypertension 1999; 33: 1130-4.
84. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase inblood glucose concentration during antihypertensive treatment as apredictor of myocardial infarction: population based cohort study. BMJ 2003; 326: 681-5.
85. Davey SG, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH. Incidence of type 2 diabetes in the randomized multiplerisk factor intervention trial. Ann Intern Med 2005; 142: 313-22.
86. Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatmentand serum lipoproteins. J Hypertens 1985; 3: 297-306.
87. Rosenthal T, Holtzman E, Segal P. The effect of chlorthalidone onserum lipids and lipoproteins. Atherosclerosis 1980; 36: 111-5.
88. Glück Z, Baumgartner G, Weidmann P, et al. Increased ratio betweenserum beta and alpha-lipoproteins during diuretic therapy:an adverse effect? Clin Sci Mol Med Suppl 1978; 4: 325s-328s.
89. Freis ED. The efficacy and safety of diuretics in treating hypertension.Ann Intern Med 1995; 122: 223-6.
90. Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M.Long-term experience with indapamide. Am Heart J 1983; 106 (1Pt 2): 258-62.
91. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensivetherapy on serum lipids. Ann Intern Med 1995; 122: 133-41.
92. Lehtonen A. Comparison of the metabolic effects of long-termtreatment with pindolol or atenolol by hypertensive patients. CardiovascDrugs Ther 1988; 1: 549-51.
93. Sirtori CR, Johnson B, Vaccarino V, et al. Lipid effects ofceliprolol, a new cardioselective beta-blocker vs. propranolol. ClinPharmacol Ther 1989; 45: 617-26.
94. Lijnen P. Biochemical mechanisms involved in the beta-blockerinducedchanges in serum lipoproteins. Am Heart J 1992; 124: 549-56.
95. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol andpropranolol in a double-blind cross-over study in hypertensive patients.Blood Press 1992; 1: 92-101.
96. Ames RP. The effects of antihypertensive drugs on serum lipidsand lipoproteins. II. Non-diuretic drugs. Drugs 1986; 32: 335-57.
97. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M. ACE inhibition improves insulin-sensitivity in agedinsulin-resistant hypertensive patients. J Hum Hypertens 1992; 6:175-9.
98. Berne C. Metabolic effects of ACE inhibitors. J Intern Med 1991;735 (Suppl 2): 119-25.
99. Schlueter W, Keilani T, Batlle DC. Metabolic effects of convertingenzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril. Am J Cardiol 1993; 72: 37H-44H.
100. Weinberger MH. Influence of an angiotensin converting-enzymeinhibitor on diuretic-induced metabolic effects in hypertension.Hypertension 1983; 5 (5 Pt 2): III132-III138.
101. Kyvelou SM, Vyssoulis GP, Karpanou EA, et al. Effects of antihypertensivetreatment with angiotensin II receptor blockers onlipid profile: an open multi-drug comparison trial. Hellen J Cardiol 2006; 47: 21-8.
102. Hanefeld M, Abletshauser C. Effect of the angiotensin II receptorantagonist valsartan on lipid profile and glucose metabolism in patientswith hypertension. J Int Med Res 2001; 29: 270-9.
103. Tagami T, Yamamoto H, Moriyama K, et al. A selective peroxisomeproliferator-activated receptor-gamma modulator, telmisartan,binds to the receptor in a different fashion from thiazolidinediones.Endocrinology 2009; 150: 862-70.
104. Rizos CV, Elisaf MS, Liberopoulos EN. Are the pleiotropic effectsof telmisartan clinically relevant? Curr Pharm Des 2009; 15: 2815-32.
105. Elisaf M, Liberopoulos EN. Are the pleiotropic effects of drugsused for the prevention of cardiovascular disease clinically relevant? Curr Pharm Des 2009; 15: 463-6.
106. Rizos CV, Milionis HJ, Kostapanos MS, et al. A 24-week,prospective, open-label, randomized evaluation of the effect ofrosuvastatin plus olmesartan, irbesartan or telmisartan combinationtreatment on glucose metabolism indices in Greek adult patientswith impaired fasting glucose hypertension and mixedhyperlipidemia. Clin Ther 2010; in press.
107. Spirou A, Rizos E, Liberopoulos EN, et al. Effect of barnidipine onblood pressure and serum metabolic parameters in patients with essentialhypertension: a pilot study. J Cardiovasc Pharmacol Ther 2006; 11: 256-61.
108. Schulte KL, Meyer-Sabellek WA, Haertenberger A, et al. Antihypertensiveand metabolic effects of diltiazem and nifedipine.Hypertension 1986; 8: 859-65.
109. Pool PE, Seagren SC, Salel AF. Effects of diltiazem on serumlipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension.Am J Cardiol 1985; 56: 86H-91H.
110. Lardinois CK, Neuman SL. The effects of antihypertensive agentson serum lipids and lipoproteins. Arch Intern Med 1988; 148:1280-8.
111. Moser M. Antihypertensive medications: relative effectiveness andadverse reactions. J Hypertens 1990; 8 (Suppl 2): S9-S16.
112. Rohlfing JJ, Brunzell JD. The effects of diuretics and adrenergicblockingagents on plasma lipids. West J Med 1986; 145: 210-8.
113. Giles TD. Antihypertensive therapy and cardiovascular risk. Are allantihypertensives equal? Hypertension 1992; 19 (Suppl 1): I124-I129.
114. Gleerup G, Petersen JR, Mehlsen J, Winther K. Effect of spirapriland hydrochlorothiazide on platelet function and euglobulin clot lysistime in patients with mild hypertension. Angiology 1996; 47:951-5.
115. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition vs.angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 2002; 40: 859-65.
116. Ma J, Albornoz F, Yu C, Byrne DW, Vaughan DE, Brown NJ.Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.Hypertension 2005; 46: 313-20.
117. Mugellini A, Preti P, Zoppi A, et al. Effect of delapril-manidipinecombination vs. irbesartan-hydrochlorothiazide combination on fibrinolyticfunction in hypertensive patients with type II diabetesmellitus. J Hum Hypertens 2004; 18: 687-91.
118. Muravyov AV, Meiselman HJ, Yakusevich VV, Zamishlayev AV. Effects of antihypertensive therapy on hemorheological profiles infemale hypertensive patients with initially low or high whole bloodviscosity. Clin Hemorheol Microcirc 2002; 26: 125-35.
119. Achimastos A, Liberopoulos E, Nikas S, et al. The effects of theaddition of micronised fenofibrate on uric acid metabolism in patientsreceiving indapamide. Curr Med Res Opin 2002; 18: 59-63.
120. Tsagadopoulos D, Antonakoudis H, Makris T, et al. Effect of antihypertensivetreatment on lipids and fibrinogen: Greek multicentrestudy of cilazapril. Cardiology 1996; 87: 524-8.
121. Kobusiak-Prokopowicz M, Jołda-Mydłowska B, Zubkiewicz A, Szymczak M, Mysiak A, Skalik R. Impact of nebivolol on levels ofserum nitric oxide, plasma von Willebrand factor and exercisestress testing parameters in hypertensive and ischemic heart diseasepatients. Cardiol J 2008; 15: 162-8.
122. Tarighi B, Kurum T, Demir M, Azcan SN. The effects of nebivololon fibrinolytic parameters in mild and moderate hypertensive patients.Can J Cardiol 2007; 23: 651-5.
123. Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivololplus pravastatin is associated with a more beneficial metabolicprofile compared to that of atenolol plus pravastatin in hypertensivepatients with dyslipidemia: a pilot study. J CardiovascPharmacol Ther 2003; 8: 127-34.
124. Vyssoulis GP, Marinakis AG, Aznaouridis KA, et al. The impact ofthird-generation beta-blocker antihypertensive treatment on endothelialfunction and the prothrombotic state: effects of smoking.Am J Hypertens 2004; 17: 582-9.
125. Westheim A, Daae LN, Kierulf P, Brusletto B, Holme I, Syvertsen JO. Selective alpha 1 inhibition with doxazosin in hypertensivesmokers and non-smokers: haemodynamic and metabolic effects. JHypertens Suppl 1990; 8: S41-6.
126. Jagroop IA, Mikhailidis DP. Doxazosin, an alpha1-adrenoceptorantagonist, inhibits serotonin-induced shape change in humanplatelets. J Hum Hypertens 2001; 15: 203-7.
127. Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipineatorvastatincombination on fibrinolysis in hypertensive hypercholesterolemicpatients with insulin resistance. Am J Hypertens 2004;17: 823-7.
128. De Luca N, Izzo R, Fontana D, et al. Haemodynamic and metaboliceffects of rilmenidine in hypertensive patients with metabolicsyndrome X. A double-blind parallel study vs. amlodipine. J Hypertens 2000; 18: 1515-22.
129. Winther K, Gleerup G, Hedner T. Platelet function and fibrinolyticactivity in hypertension: differential effects of calcium antagonistsand beta-adrenergic receptor blockers. J Cardiovasc Pharmacol 1991; 18 (Suppl 9): S41-S44.
130. Jeremy JY, Barradas MA, Mikhailidis DP, Dandona P. An investigationinto the effects of nifedipine and nimodipine on plateletfunction and vascular prostacyclin synthesis. Drugs Exp Clin Res 1985; 11: 645-51.
131. Jastrzebskal M, Widecka K, Naruszewicz M, et al. Effects of perindopriltreatment on hemostatic function in patients with essentialhypertension in relation to angiotensin converting enzyme (ACE)and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms.Nutr Metab Cardiovasc Dis 2004; 14: 259-69.
132. Yajima K, Shimada A, Hirose H, et al. Effect on the atherogenicmarker plasminogen activator inhibitor type-1 of addition of theACE inhibitor imidapril to angiotensin II type 1 receptor antagonisttherapy in hypertensive patients with abnormal glucose metabolism:a prospective cohort study in primary care. Clin Drug Investig 2009; 29: 811-9.
133. Hlubocká Z, Umnerová V, Heller S, et al. Circulating intercellularcell adhesion molecule-1, endothelin-1 and von Willebrand factormarkersof endothelial dysfunction in uncomplicated essential hypertension:the effect of treatment with ACE inhibitors. J Hum Hypertens 2002; 16: 557-62.
134. Gasic S, Wagner OF, Fasching P, et al. Fosinopril decreases levelsof soluble vascular cell adhesion molecule-1 in borderline hypertensivetype II diabetic patients with microalbuminuria. Am J Hypertens 1999; 12: 217-22.
135. Trifiletti A, Barbera N, Scamardi R, et al. Effects of medium-termantihypertensive therapy on haemostatic parameters in patientswith essential hypertension. Haemostasis 1997; 27: 35-8.
136. Ekholm M, Wallén NH, Johnsson H, Eliasson K, Kahan T. Longtermangiotensin-converting enzyme inhibition with ramipril reducesthrombin generation in human hypertension. Clin Sci (Lond) 2002; 103: 151-5.
137. James IM, Dickenson EJ, Burgoyne W, et al. Treatment of hypertensionwith captopril: preservation of regional blood flow and reducedplatelet aggregation. J Hum Hypertens 1988; 2: 21-5.
138. Persson F, Rossing P, Hovind P, et al. Irbesartan treatment reducesbiomarkers of inflammatory activity in patients with type 2 diabetesand microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55:3550-5.
139. Makris TK, Stavroulakis G, Papadopoulos DP, et al. Eprosartaneffect on fibrinolytic/hemostatic variables in arterial hypertension:a comparative study to losartan. Drugs Exp Clin Res 2004; 30: 125-32.
140. Rayner BL, Trinder YA, Baines D, Isaacs S, Opie LH. Effect oflosartan vs. candesartan on uric acid, renal function, and fibrinogenin patients with hypertension and hyperuricemia associated withdiuretics. Am J Hypertens 2006; 19: 208-13.
141. Elisaf M, Tsimichodimos V, Bairaktari E, Siamopoulos KC. Effectof micronized fenofibrate and losartan combination on uric acidmetabolism in hypertensive patients with hyperuricemia. J CardiovascPharmacol 1999; 34: 60-3.
142. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensinII receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-10.
143. Hermida RC, Calvo C, Ayala DE, López JE. Decrease in urinaryalbumin excretion associated with the normalization of nocturnalblood pressure in hypertensive subjects. Hypertension 2005; 46:960-8.
144. Agirbasli M, Cincin A, Baykan OA. Short-term effects of angiotensinreceptor blockers on blood pressure control, and plasma inflammatoryand fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors. J Renin Angiotensin AldosteroneSyst 2008; 9: 22-6.
145. Paterna S, Di Garbo V, Avellone G, et al. Effects of losartan anddelapril on the fibrinolytic system in patients with mild to moderatehypertension. Clin Drug Investig 2003; 23: 717-24.
146. Skurk T, Lee YM, Nicuta-Rölfs TO, Haastert B, Wirth A, Hauner H. Effect of the angiotensin II receptor blocker candesartan on fibrinolysisin patients with mild hypertension. Diabetes Obes Metab 2004; 6: 56-62.
147. Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension.Am J Cardiol 2000; 86: 1188-92.
148. Liu L, Zhao SP, Zhou HN, Li QZ, Li JX. Effect of fluvastatin andvalsartan, alone and in combination, on postprandial vascular inflammationand fibrinolytic activity in patients with essential hypertension.J Cardiovasc Pharmacol 2007; 50: 50-5.
149. Rizos EC, Spyrou A, Liberopoulos EN, et al. Effects of eprosartanon serum metabolic parameters in patients with essential hypertension.Open Cardiovasc Med J 2007; 1: 22-6.
150. Paterna S, Di Garbo V, Avellone G, et al. Different effects of losartanand delapril on plasma PAI-1 levels in patients with mild tomoderate hypertension. Int J Cardiol 2003; 92: 303-4.
151. Koh KK, Chung WJ, Ahn JY, et al. Angiotensin II type 1 receptorblockers reduce tissue factor activity and plasminogen activator inhibitortype-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 2004; 177:155-60.
152. Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiateshape change in human platelets: effect of losartan. J Hum Hypertens 2000; 14: 581-5.
153. Nielsen FS, Rossing P, Gall MA, et al. Lisinopril improves endothelialdysfunction in hypertensive NIDDM subjects with diabeticnephropathy. Scand J Clin Lab Invest 1997; 57: 427-34.
154. Chung NA, Beevers DG, Lip G. Effects of losartan vs. hydrochlorothiazideon indices of endothelial damage/dysfunction, angiogenesisand tissue factor in essential hypertension. Blood Press 2004; 13: 183-9.
155. Gleerup G, Mehlsen J, Winther K. Does calcium channel blockadeand beta-adrenergic blockade affect platelet function and fibrinolysisto a varying degree? J Cardiovasc Pharmacol 1995; 25: 87-9.
156. Koenig W, Sund M, Ernst E, et al. Effects of felodipine ER andhydrochlorothiazide on blood rheology in essential hypertension-arandomized, double-blind, crossover study. J Intern Med 1991;229: 533-8.
157. Fogari R, Zoppi A, Malamani GD, Marasi G, Vanasia A, Villa G.Effects of different antihypertensive drugs on plasma fibrinogen inhypertensive patients. Br J Clin Pharmacol 1995; 39: 471-6.
158. Makris TK, Stavroulakis GA, Krespi PG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response totreatment with irbesartan or atenolol. Am J Hypertens 2000; 13:783-8.
159. Boman K, Boman JH, Andersson J, Olofsson M, Dahlof B. Effectsof atenolol or losartan on fibrinolysis and von Willebrand factor inhypertensive patients with left ventricular hypertrophy. Clin ApplThromb Hemost 2010; 16: 146-52.
160. Spencer CG, Felmeden DC, Blann AD, Lip GY. Effects of "newer"and "older" antihypertensive drugs on hemorrheological, platelet,and endothelial factors. A substudy of the Anglo-ScandinavianCardiac Outcomes Trial. Am J Hypertens 2007; 20: 699-704.
161. Seljeflot I, Arnesen H, Andersen P, Aspelin T, Kierulf P. Effects ofdoxazosin and atenolol on circulating endothelin-1 and von Willebrandfactor in hypertensive middle-aged men. J Cardiovasc Pharmacol 1999; 34: 584-8.
162. Andersen P, Seljeflot I, Herzog A, Arnesen H, Hjermann I, Holme I. Effects of doxazosin and atenolol on atherothrombogenic riskprofile in hypertensive middle-aged men. J Cardiovasc Pharmacol 1998; 31: 677-83.
163. Jansson JH, Johansson B, Boman K, Nilsson TK. Effects of doxazosinand atenolol on the fibrinolytic system in patients with hypertensionand elevated serum cholesterol. Eur J Clin Pharmacol 1991;40: 321-6.
164. Islim IF, Bareford D, Beevers DG. A single (investigator)-blindrandomized control trial comparing the effects of quinapril andnifedipine on platelet function in patients with mild to moderatehypertension. Platelets 2001; 12: 274-8.
165. Sakata K, Shirotani M, Yoshida H, Urano T, Takada Y, Takada A.Differential effects of enalapril and nitrendipine on the fibrinolyticsystem in essential hypertension. Am Heart J 1999; 137: 1094-9.
166. Pahor M, Franse LV, Deitcher SR, et al. Fosinopril vs. amlodipinecomparative treatments study: a randomized trial to assess effectson plasminogen activator inhibitor-1. Circulation 2002; 105: 457-61.
167. Agabiti RE, Morelli P, Rizzoni D. Effects of nifedipine GITS 20mg or enalapril 20 mg on blood pressure and inflammatory markersin patients with mild-moderate hypertension. Blood Press Suppl 2005; 1: 14-22.
168. Fogari R, Preti P, Lazzari P, et al. Effect of benazepril amlodipinecombination on fibrinolysis in hypertensive diabetic patients. Eur JClin Pharmacol 2003; 59: 271-5.
169. Sakata K, Pawlak R, Urano T, Takada A. Effects of a long-termpharmacological interruption of the renin-angiotensin system onthe fibrinolytic system in essential hypertension. PathophysiolHaemost Thromb 2002; 32: 67-75.
170. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A.Differential effects of ACE-inhibition and angiotensin II antagonismon fibrinolysis and insulin sensitivity in hypertensive postmenopausalwomen. Am J Hypertens 2001; 14: 921-6.
171. Fogari R, Zoppi A, Lazzari P, et al. ACE inhibition but not angiotensinII antagonism reduces plasma fibrinogen and insulin resistancein overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32: 616-20.
172. Li-Saw-Hee FL, Beevers DG, Lip GY. Effect of antihypertensivetherapy using enalapril or losartan on haemostatic markers in essentialhypertension: a pilot prospective randomised double-blindparallel group trial. Int J Cardiol 2001; 78: 241-6.
173. Leu HB, Charng MJ, Ding PY. A double blind randomized trial tocompare the effects of eprosartan and enalapril on blood pressure,platelets, and endothelium function in patients with essential hypertension. Jpn Heart J 2004; 45: 623-35.
174. Hirschl MM, Bur A, Woisetschlaeger C, Derhaschnig U, Laggner AN. Effects of candesartan and lisinopril on the fibrinolytic systemin hypertensive patients. J Clin Hypertens (Greenwich) 2007; 9:430-5.
175. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindoprileffects on plasma plasminogen activator inhibitor-1 and fibrinogenin hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15:316-20.
176. Agabiti Rosei E, Rizzoni D, Muiesan ML, et al. Effects of candesartancilexetil and enalapril on inflammatory markers of atherosclerosisin hypertensive patients with non-insulin-dependent diabetesmellitus. J Hypertens 2005, 23: 435-44.
177. Erdem Y, Usalan C, Haznedaroǧlu IC, et al. Effects of angiotensinconverting enzyme and angiotensin II receptor inhibition on impairedfibrinolysis in systemic hypertension. Am J Hypertens 1999;12: 1071-6.
178. Remková A, Kratochvílová H, Durina J. Impact of the therapy byrenin-angiotensin system targeting antihypertensive agents perindoprilvs. telmisartan on prothrombotic state in essential hypertension. J Hum Hypertens 2008; 22: 338-45.
179. Lynch AI, Boerwinkle E, Davis BR, et al. Antihypertensive pharmacogeneticeffect of fibrinogen-beta variant -455G>A on cardiovasculardisease, end-stage renal disease, and mortality: the Gen-HAT study. Pharmacogenet Genomics 2009; 19: 415-21.
180. Karagiannis A, Hatzitolios AI, Athyros VG, et al. Implementationof guidelines for the management of arterial hypertension. The IMPULSIONstudy. Open Cardiovasc Med J 2009; 3: 26-34.
181. Stepien M, Banach M, Mikhailidis DP, Gluba A, Kjeldsen SE, Rysz J. Role and significance of statins in the treatment of hypertensivepatients. Curr Med Res Opin 2009; 25: 1995-2005.